Leap Therapeutics is a biopharmaceutical company developing novel therapeutics at the leading edge of cancer research.
View Latest Company Presentation
View DKN-01 Program Update Webcast (May 18, 2018)
Our most advanced clinical programs are monoclonal antibodies that target key cellular pathways that enable cancer to grow and proliferate, known as cancer cell signaling, and pathways that enable the body’s immune system to identify and attack cancer.
Our accomplished leadership and development team, working together for over 20 years, has comprehensive and proven experience developing transformational therapies.
Therapies targeting cancer cell signaling and T cells may offer new options for patients with cancer.
